The epidermolysis bullosa (EB) market is predicted to grow at a compound annual growth rate of approximately 8% between 2019 and 2032 according to Delvelnsight. 1 The business consultant and market research firm announced growth can be attributed to the increase in clinical and genetic testing, recent approvals of potential gene-based therapies, and the anticipated launch of emerging therapies to treat EB. Olivier Le Moal/AdobeStock “Delvelnsight’s Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices, epidermolysis bullosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented […]
Click here to visit source. www.dermatologytimes.com